Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

NCT00928330 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: GDC-0941
DRUG: Trastuzumab
DRUG: trastuzumab-MCC-DM1

Sponsor

Genentech, Inc.